Pfizer Has Tafamidis Data In Hand, But Market Development Still A Challenge

Unveiling its Phase III data showing both an all-cause mortality and cardiovascular hospitalization benefit, Pfizer thinks it can bring dramatic improvement in therapy for transthyretin cardiomyopathy.

Anatomy of Human Heart

Phase III data showing tafamidis can reduce all-cause mortality and cardiovascular-related hospitalization has Pfizer Inc. anticipating a potential rare disease blockbuster, but it conceded Aug. 27 that first it will have make substantial efforts to build the market in transthyretin cardiomyopathy (ATTR-CM).

Analysts swooned at the data showing a 30% reduction in all-cause mortality and 32% decrease in cardiovascular-related hospitalization at 30 months compared with placebo, projecting a future blockbuster for Pfizer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D